Get the Stockscreener App
3.52
0.85%
-0.03
After Hours:
3.65
0.13
+3.69%
Eledon Pharmaceuticals Inc stock is traded at $3.52, with a volume of 573.23K.
It is down -0.85% in the last 24 hours and down -8.81% over the past month.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
See More
Previous Close:
$3.55
Open:
$3.53
24h Volume:
573.23K
Relative Volume:
0.46
Market Cap:
$286.04M
Revenue:
-
Net Income/Loss:
$-78.15M
P/E Ratio:
-4.1059
EPS:
-0.8573
Net Cash Flow:
$-68.89M
1W Performance:
-4.86%
1M Performance:
-8.81%
6M Performance:
+60.73%
1Y Performance:
+36.43%
1-Day Range:
$3.42
$3.5935
1-Week Range:
$3.42
$3.7393
52-Week Range:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.52 | 288.48M | 0 | -78.15M | -68.89M | -0.8573 |
VRTX
Vertex Pharmaceuticals Inc
|
540.26 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.64 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,038.12 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
133.32 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.74 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Eledon Pharmaceuticals (NASDAQ:ELDN) Upgraded at Wall Street Zen - MarketBeat
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Pharmaceuticals (ELDN) Slips 1.86% as Shares Test Key Support at $3.52Breakout Confirmation - Vinanet
Eledon Pharmaceuticals (NASDAQ:ELDN) Posts Quarterly Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Eledon Pharmaceuticals Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals (ELDN) - Zacks Investment Research
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Eledon Q2 EPS misses estimates as net loss widens 182% YoY - scanx.trade
Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3 - Stock Titan
Eledon Islet Study: All 12 Patients Reached Insulin Independence - Stock Titan
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Meets Mild Share UptickInterim Report - Vinanet
Eledon Pharmaceuticals (ELDN) Holds Above $3.60 Support After Modest AdvanceAnchored VWAP - Vinanet
Midday Stock Roundup: Eledon Falls 3.5% - Orange County Business Journal
ELDN Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesLong-Term Guidance - Vinanet
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Eledon Pharmaceuticals (ELDN) Institutional Ownership 2026 - MarketBeat
Eledon Pharmaceuticals (ELDN) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals (ELDN) Gains 2.19% as Shares Trade Between Key LevelsIron Condor Alert - Vinanet
Eledon Pharmaceuticals Inc. (ELDN) Q1 2026 Earnings: EPS Misses Estimates by 77.23% as Stock DeclinesRevenue Guidance Update - Vinanet
Vanguard Capital Management (ELDN) discloses 5.05% passive stake in Eledon Pharmaceuticals - Stock Titan
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
ADAR1 Capital Management LLC Has $3 Million Position in Eledon Pharmaceuticals, Inc. $ELDN - MarketBeat
Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eledon: At The Center Of The Next Medical Frontier (NASDAQ:ELDN) - Seeking Alpha
Eledon Pharmaceuticals Inc (ELDN) Cash Flow - TradingKey
Eledon Pharmaceuticals Inc (ELDN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Eledon Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ELDN - TradingView
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation - Sahm
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Eledon Pharmaceuticals, Inc. (ELDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Eledon’s BESTOW Trial Completion: What Tegoprubart Could Mean for Transplant Investing - TipRanks
Eledon Pharmaceuticals Q1 2026 Earnings: Wider-than-Expected Loss Weighs on SharesTax Rate Impact - Vinanet
ELDN Initiated Coverage by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Eledon Pharmaceuticals stock initiated at Buy by Rodman & Renshaw - Investing.com Canada
Eledon Pharmaceuticals (ELDN) Drops 7.5%: Key Support Tested Amid Biotech VolatilityProfit Surge Picks - dars.gov.et
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy - Sahm
Eledon Pharmaceuticals (ELDN) Edges Higher as Stock Approaches Key Resistance at $4.15Leading Diagonal - dars.gov.et
NewcelX receives FDA feedback on type 1 diabetes therapy plan - Investing.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 3000 Value Benchmark - marketscreener.com
Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 2000 Value Benchmark - marketscreener.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to EBITDA forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Price to earnings forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Price to earnings forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Price to sales forward of Eledon Pharmaceuticals, Inc. – NASDAQ:ELDN - TradingView
Enterprise value to revenue forward of Eledon Pharmaceuticals, Inc. – SWB:2TK - TradingView
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):